Cytosorbents/CTSO

$1.02

0.99%
-
1D1W1MYTD1YMAX

About Cytosorbents

CytoSorbents Corporation is engaged in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its polymer adsorption technology. Its lead product, CytoSorb, is an extracorporeal cytokine absorber, designed to reduce the cytokine storm or cytokine release syndrome that could otherwise cause massive inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury, cytokine release syndrome due to cancer immunotherapy, and pancreatitis. Its other products include CytoSorb, animal-targeted VetResQ, DrugSorb-ATR, ECOS-300CY. Its other product candidates under development, including CytoSorb XL, BetaSorb, ContrastSorb, DrugSorb, HemoDefend-RBC, HemoDefend-BGA, K+ontrol, and others consist of a cartridge containing adsorbent, porous polymer beads, although the polymers used in these devices are physically different.
Ticker
CTSO
Sector
Healthcare
Trading on
NASDAQ
Industry
Medical Equipment & Supplies
CEO
Phillip Chan
Employees
198
Headquarters
Princeton, United States

Cytosorbents Metrics

BasicAdvanced
$52.73M
Market cap
-
P/E ratio
-$0.53
EPS
0.60
Beta
-
Dividend rate

What the Analysts think about Cytosorbents

Analyst Ratings

Majority rating from 4 analysts.
Buy

Price Targets

Average projection from 5 analysts.
262.75% upside
High $6.50
Low $1.00
$1.02
Current price
$3.70
Average price target

Cytosorbents Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-103.4% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$8.8M
-53.19%
Net income
$-9.1M
-32.09%
Profit margin
-103.4%
45.08%

Cytosorbents Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 52.17%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.02
-$0.17
-$0.14
-$0.21
-
Expected
-$0.17
-$0.13
-$0.11
-$0.14
-$0.14
Surprise
-88.1%
34.21%
24.44%
52.17%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Cytosorbents stock

Buy or sell Cytosorbents stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing